The Canadian drugmaker, the target of U.S. investigations into its business and accounting practices, reiterated that it would delay filing its annual report with U.S. regulators but for the first time raised the specter of a default as a result. As of Sept. 30, Valeant had about $30 billion of long-term debt. The company said last month it would delay filing its annual report while a board committee looked into its accounting practices.
The rest is here:
Valeant cuts 2016 forecasts, says report delay poses default risk
